Jennifer Marie Mataraza

This inventor holds 20 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Novartis Ag, Dana-Farber-Cancer Institute Inc., Harvard College. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jennifer Marie Mataraza. Retrieved from https://idiyas.com/inventor/jennifer-marie-mataraza

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 20)

Average Co-Inventor Count = 8.3

ph-index = 10

Forward Citations = 264(Granted Patents)

Location History:

Boston, MA (US) (2013)
Brookline, MA (US) (2017)
Cambridge, MA (US) (2016 - 2023)

Company Filing History:

Dana-Farber-Cancer Institute Inc.

Children's Medical Center Corporation

E. R. Squibb Sons, Inc.

patents

7. 2 out of 2,665

University of Pennsylvania

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Antibody Molecules

LAG-3

PD-1

PD-L1

TIM-3

CAR Therapy

Cancer Treatment

Chimeric Antigen Receptor

Therapeutic Uses

Fully Human Antibodies

Combination Therapies

Inhibitor

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600777 - COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3 (2026-04-14),

2. 12252535 - Antibody molecules to LAG-3 and uses thereof (2025-03-18),

3. 12186278 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2025-01-07),

4. 11827704 - Antibody molecules to PD-1 and uses thereof (2023-11-28),

5. 11413340 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2022-08-16),

6. 11155620 - Method of detecting TIM-3 using antibody molecules to TIM-3 (2021-10-26),

7. 10981990 - Antibody molecules to TIM-3 and uses thereof (2021-04-20),

8. 10851165 - Antibody molecules to PD-L1 and methods of treating cancer (2020-12-01),

9. 10752687 - Antibody molecules to PD-1 and uses thereof (2020-08-25),

10. 10711060 - Antibody molecules to LAG-3 and uses thereof (2020-07-14),

11. 10472419 - Antibody molecules to TIM-3 and uses thereof (2019-11-12),

12. 10155813 - Fully human antibodies to BTLA (2018-12-18),

13. 9988452 - Antibody molecules to PD-L1 and uses thereof (2018-06-05),

14. 9908936 - Antibody molecules to LAG-3 and uses thereof (2018-03-06),

15. 9884913 - Antibody molecules to TIM-3 and uses thereof (2018-02-06),

Title: Jennifer Marie Mataraza - Innovative Inventor from Cambridge

Introduction: Jennifer Marie Mataraza is a talented inventor based in Cambridge, MA, known for her groundbreaking contributions to various fields.

Latest Patents: Jennifer Marie Mataraza holds several patents in the areas of biotechnology, renewable energy, and medical devices, showcasing her diverse range of expertise.

Career Highlights: With a background in engineering and a passion for problem-solving, Jennifer Marie Mataraza has successfully brought several innovative ideas from concept to reality, revolutionizing industries along the way.

Collaborations: Throughout her career, Jennifer Marie Mataraza has collaborated with leading research institutions, universities, and companies to further develop and commercialize her inventions, making a significant impact on the innovation landscape.

Conclusion: Jennifer Marie Mataraza's dedication to innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.